Navigating Uncertainty: A Review of Health Economic Evaluations

The Importance of Uncertainty Assessment

Health Economic Evaluations (HEEs) play a crucial role in reimbursement decisions, particularly in the realm of healthcare technologies. However, these evaluations are often fraught with uncertainty, posing significant challenges to decision-makers. The assessment of uncertainty is a cornerstone of these evaluations, helping to gauge the robustness of results and the potential consequences of uncertainty related to decisions. Yet, there is currently no comprehensive overview of the methods used for uncertainty assessment in HEEs.

Exploring the Methods of Uncertainty Assessment

A recent review aimed to fill this gap, exploring the various methods used for uncertainty assessment in model-based HEEs. The review identified a total of 80 different methods for assessing uncertainty: 30 for identification, 28 for analysis, and 22 for communication. These methods cater to different sources of uncertainty, with most identification methods developed to assess related concepts like validity, model quality, and relevance.

This review aids analysts and decision-makers by guiding them to choose suitable uncertainty assessment techniques based on their specific needs and the overall assessment purpose. However, it also highlights the need for more precise terminology and guidance on using these methodologies.

In conclusion, assessing uncertainty is crucial in HEEs. The paper below offers a comprehensive review of the methods the industry is currently using. Nevertheless, additional work is necessary to both clarify language and provide direction on the application of these methodologies.

DTC Telehealth Partnerships: Navigating Risks in Pharma’s Digital Expansion

July 18, 2025 Staff Writer

🚀 Are pharmaceutical companies’ DTC telehealth partnerships reshaping healthcare for better or worse?

Recent findings from the “DTC Investigation 2025” report reveal key insights into the high prescription rates and potential risks of these digital platforms operated by giants like Pfizer and Eli Lilly. Alarmingly, inadequate clinical safeguards raise questions about patient safety, prescribing practices, and cost implications.

Dive into this critical discussion about the intersection of digital health and pharmaceutical practices, and explore what it means for the future of patient care.

#SyenzaNews #DigitalHealth #HealthEconomics #HealthcarePolicy

MAF Test Breast Cancer: Revolutionizing Personalized Treatment in Spanish Oncology

July 17, 2025 João L. Carapinha

🌟 How can personalized medicine transform breast cancer treatment in Spain?

The recent rollout of the MAF Test breast cancer in leading Spanish hospitals is set to revolutionize patient care by enabling targeted treatment strategies. This innovative molecular assay not only identifies patients who will benefit from bisphosphonates but also spares those for whom the treatment may be harmful, ultimately improving outcomes for thousands.

Dive into the article to discover how this approach aligns with global trends in oncology and enhances healthcare resource allocation.

#SyenzaNews #precisionmedicine #HealthEconomics #innovation

NICE’s Ribociclib Breast Cancer Guidance: A New Era for High-Risk Patients in the NHS

July 17, 2025 João L. Carapinha

🌟 Are we on the brink of transforming breast cancer treatment?

NICE’s latest guidance endorsing ribociclib in combination with an aromatase inhibitor marks a significant advancement for adults facing high-risk early breast cancer. This decision not only promises enhanced survival outcomes but also expands treatment options for patients historically limited to conventional therapies.

Dive into the details of this important development and learn how it may revolutionize patient care in the oncology landscape.

#SyenzaNews #oncology #costeffectiveness #MarketAccess